EUR 0.53
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 8 Million EUR | -11.33% |
2022 | 9.02 Million EUR | -6.05% |
2021 | 9.6 Million EUR | 8.87% |
2020 | 8.82 Million EUR | 30.74% |
2019 | 6.74 Million EUR | -21.38% |
2018 | 8.58 Million EUR | -0.77% |
2017 | 8.64 Million EUR | 13.96% |
2016 | 7.58 Million EUR | -11.95% |
2015 | 8.61 Million EUR | -6.0% |
2014 | 9.17 Million EUR | 58.55% |
2013 | 5.78 Million EUR | -26.36% |
2012 | 7.85 Million EUR | 12.73% |
2011 | 6.96 Million EUR | -14.82% |
2010 | 8.18 Million EUR | 95.36% |
2009 | 4.18 Million EUR | 17.07% |
2008 | 3.57 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 6.21 Million EUR | 0.0% |
2023 Q2 | 10.75 Million EUR | 0.0% |
2023 FY | 8 Million EUR | -11.33% |
2023 Q4 | 8 Million EUR | 0.0% |
2022 Q4 | 9.02 Million EUR | 0.0% |
2022 Q2 | 9.35 Million EUR | 0.0% |
2022 FY | 9.02 Million EUR | -6.05% |
2021 Q4 | 9.6 Million EUR | 0.0% |
2021 FY | 9.6 Million EUR | 8.87% |
2021 Q2 | 8.2 Million EUR | 0.0% |
2020 FY | 8.82 Million EUR | 30.74% |
2020 Q2 | 9.5 Million EUR | 0.0% |
2020 Q4 | 8.82 Million EUR | 0.0% |
2019 Q4 | 6.74 Million EUR | 0.0% |
2019 Q2 | 7.06 Million EUR | 0.0% |
2019 FY | 6.74 Million EUR | -21.38% |
2018 Q2 | 6.88 Million EUR | 0.0% |
2018 FY | 8.58 Million EUR | -0.77% |
2018 Q4 | 8.58 Million EUR | 0.0% |
2017 Q2 | 8.87 Million EUR | 0.0% |
2017 FY | 8.64 Million EUR | 13.96% |
2017 Q4 | 8.64 Million EUR | 0.0% |
2016 Q2 | 7.39 Million EUR | 0.0% |
2016 Q4 | 7.58 Million EUR | 0.0% |
2016 FY | 7.58 Million EUR | -11.95% |
2015 Q2 | 8.13 Million EUR | 0.0% |
2015 FY | 8.61 Million EUR | -6.0% |
2015 Q4 | 8.61 Million EUR | 0.0% |
2014 Q4 | 9.17 Million EUR | 0.0% |
2014 FY | 9.17 Million EUR | 58.55% |
2014 Q2 | 8.9 Million EUR | 0.0% |
2013 Q4 | 5.78 Million EUR | 0.0% |
2013 FY | 5.78 Million EUR | -26.36% |
2013 Q2 | 6.88 Million EUR | 0.0% |
2012 Q4 | 7.85 Million EUR | 0.0% |
2012 Q2 | 6.47 Million EUR | 0.0% |
2012 FY | 7.85 Million EUR | 12.73% |
2011 FY | 6.96 Million EUR | -14.82% |
2011 Q2 | 7.93 Million EUR | 0.0% |
2011 Q4 | 6.96 Million EUR | 0.0% |
2010 Q4 | 8.18 Million EUR | 0.0% |
2010 FY | 8.18 Million EUR | 95.36% |
2010 Q2 | 9.79 Million EUR | 0.0% |
2009 FY | 4.18 Million EUR | 17.07% |
2008 FY | 3.57 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ABIONYX Pharma SA | 14.71 Million EUR | 45.613% |
ABIVAX Société Anonyme | 327.06 Million EUR | 97.554% |
Adocia SA | 24.95 Million EUR | 67.942% |
Aelis Farma SA | 26.28 Million EUR | 69.558% |
Biophytis S.A. | 11.93 Million EUR | 32.973% |
Advicenne S.A. | 12.4 Million EUR | 35.517% |
genOway Société anonyme | 31.84 Million EUR | 74.875% |
Medesis Pharma S.A. | 1.92 Million EUR | -315.315% |
Neovacs S.A. | 47.53 Million EUR | 83.169% |
NFL Biosciences SA | 3.97 Million EUR | -101.488% |
Plant Advanced Technologies SA | 14.91 Million EUR | 46.353% |
Quantum Genomics Société Anonyme | 3.74 Million EUR | -113.527% |
Sensorion SA | 46.49 Million EUR | 82.793% |
Theranexus Société Anonyme | 7.23 Million EUR | -10.537% |
TME Pharma N.V. | 2.49 Million EUR | -221.17% |
Valbiotis SA | 33.24 Million EUR | 75.937% |
TheraVet SA | 7.53 Million EUR | -6.187% |
Valerio Therapeutics Société anonyme | 35.27 Million EUR | 77.319% |
argenx SE | 4.11 Billion EUR | 99.805% |
BioSenic S.A. | 9.55 Million EUR | 16.306% |
Celyad Oncology SA | 16.28 Million EUR | 50.864% |
DBV Technologies S.A. | 165.65 Million USD | 95.17% |
Galapagos NV | 4.35 Billion EUR | 99.816% |
Genfit S.A. | 173.87 Million EUR | 95.399% |
GeNeuro SA | 6.31 Million EUR | -26.73% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | 83.221% |
Innate Pharma S.A. | 184.19 Million EUR | 95.657% |
Inventiva S.A. | 69.13 Million EUR | 88.429% |
MaaT Pharma SA | 42.93 Million EUR | 81.365% |
MedinCell S.A. | 36.94 Million EUR | 78.347% |
Nanobiotix S.A. | 93.89 Million EUR | 91.48% |
Onward Medical N.V. | 43.62 Million EUR | 81.663% |
Oryzon Genomics S.A. | 106.9 Million EUR | 92.516% |
OSE Immunotherapeutics SA | 81.9 Million EUR | 90.232% |
Oxurion NV | 6.55 Million EUR | -22.143% |
Pharming Group N.V. | 426.33 Million EUR | 98.123% |
Poxel S.A. | 4.82 Million EUR | -65.879% |
GenSight Biologics S.A. | 9.08 Million EUR | 11.958% |
Transgene SA | 45.21 Million EUR | 82.307% |
Financière de Tubize SA | 1.92 Billion EUR | 99.583% |
UCB SA | 15.53 Billion EUR | 99.949% |
Valneva SE | 469.39 Million EUR | 98.296% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | 74.049% |